The Food and Drug Administration has designated a drug made by Teva Pharmaceutical Industries as an orphan drug, the company said.
Use of injectable drugs for multiple sclerosis declined during the 12-month period that ended on June 30 as orally administered drugs for the condition became more popular, according to a new report.
The value of drugs approved in the United States this year could reach almost $19 billion in sales five years after their launch, exceeding the value of drugs approved in 2012, according to a new report.
The Food and Drug Administration has approved a new formulation of a cancer drug made by Teva Pharmaceutical Industries, Teva said Tuesday.
U.S.-based drug maker Perrigo Co. will buy Ireland's Elan Corp. for $8.6 billion, the companies said.
The Food and Drug Administration has approved a new treatment for multiple sclerosis made by Biogen Idec, the agency said.
Early detection of a deadly brain infection that sometimes arises due to treatment of autoimmune disorders with immune-suppressing biotech drugs may improve survival, according to a new study.
A privately owned drug maker in New York is offering $6.5 billion for Irish drug maker Elan Corp., but hasn't heard back from it, according to published reports.
Elan will sell the rights to its drug for multiple sclerosis to partnering company Biogen Idec for $3.25 billion plus royalties, the Irish drug maker said.
The Food and Drug Administration has accepted a regulatory approval application from Genzyme for an experimental treatment for multiple sclerosis, the company said Monday.
Biogen Idec is seeking Food and Drug Administration approval for a hemophilia drug that it called the first of its kind.
An experimental drug for Lou Gehrig's disease made by Biogen Idec has failed in a late-stage clinical trial, the drug maker said.
A majority of prescribers would prescribe biosimilar versions of two treatments for rheumatoid arthritis within a year of their approval, according to a new study.
The Food and Drug Administration has approved two separate dosing innovations for multiple sclerosis patients that are being treated with a Biogen Idec drug.
Drug maker Biogen Idec plans to spend up to more than $560 million to buy a company developing treatments for organ failure.
Biogen Idec has appointed a former Lenovo executive to serve as its EVP human resources.
Biogen Idec and Isis Pharmaceuticals will work together on a drug invented by Isis for spinal muscular atrophy, the two companies said.
Multiple sclerosis patients treated with a drug made by Teva Pharmaceutical Industries showed a "significant" reduction in their loss of brain volume, according to a new study.
Biogen Idec has appointed Tony Kingsley as its new EVP global commercial operations.
Biogen Idec has expanded its online resource for patients living with multiple sclerosis to include new resources and support programs.
Biogen Idec is looking to address the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis through a new educational initiative.
In a deal that will bolster its drug development capabilities, Biogen Idec has acquired a subsidiary of Swiss-based Neurimmune Holding AG.
Swiss drug maker Biogen Idec and U.S. drug maker Cardiokine have terminated an agreement to...
The drug market for Crohn's disease treatments will see moderate growth over the next decade,...
NEW YORK British drug maker GlaxoSmithKline and biotech company Genmab have started a late-stage trial...